[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-metastasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-metastasis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100534153","phase-1-safety-and-feasibility-of-intraoperative-visualization-with-cytalux-in-children-100534153",false,"NCT06235125","Safety and Feasibility of Intraoperative Visualization With Cytalux in Children","A Pilot Study of Near-Infrared Imaging Using the Novel Imaging Agent Cytalux for Adolescent Patients With Metastatic Osteosarcoma Undergoing Pulmonary Metastasectomy","Cytalux","Inclusion Criteria:\n\n1. Patients 6-17 years of age at the time of study enrollment\n2. Willingness of research participant or legal guardian\u002Frepresentative to give written informed consent\n3. Willingness of patients (subjects) age 12-17 to provide written adolescent assent\n4. Patient weight greater than or equal to 20 kg\n5. Histologically confirmed diagnosis of osteosarcoma, synovial sarcoma, hepatoblastoma, rhabdomyosarcoma, Ewing sarcoma, Wilms tumor or other non-rhabdomyosarcoma soft tissue sarcoma\n6. Imaging findings highly suspicious for pulmonary metastatic disease based on CT, PET-CT or other imaging and warranting pulmonary surgery based on the judgment of the treating team. At least one nodule ≥4mm measured by preoperative imaging.\n7. Female (assigned female at birth) participant is not pregnant and agrees to an acceptable form of contraception from the time of consent through 30 days after study intervention. Confirmed abstinence is an acceptable form of contraception.\n8. Female (assigned female at birth) participant must agree to not donate ova from time of consent until 30 days after study intervention\n9. Male (assigned male at birth) participant must agree to not donate sperm from time of consent until 30 days after study intervention.\n\nExclusion Criteria:\n\n1. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the subject\n2. History of anaphylactic reactions to products containing indocyanine green for near infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will also be excluded.\n3. History of allergy to any of the components of CYTALUX™ (PAFOLACIANINE) INJECTION\n4. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol or follow-up schedule\n5. Impaired renal function defined as eGFR\\\u003C 50 mL\u002Fmin\u002F1.73m2\n6. Impaired liver function defined as values \\> 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \\>2x ULN for total bilirubin except in subjects with Gilbert's syndrome.\n7. Patient unable or unwilling to discontinue folate, folic acid, or folate-containing supplements 48 hours before study drug administration\n8. History of drug-related serious adverse event with prior Cytalux administration will be an exclusion for re-enrollment for contralateral surgery (see section 5.7).\n9. Participants will be excluded if their 12th or 18th birthday would occur during study participation\n10. Male sex at birth and commitment to acceptable form of contraception from time of consent through 30 days after study intervention with confirmed abstinence as an acceptable form of contraception as an inclusion criterion.","ALL","6 Years","17 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach.",[28,29,30,31,32],"Osteosarcoma","Pulmonary Metastasis","Fluorescence","Metastatic Sarcoma","Pediatrics","RECRUITING","2026-06-03",{"date":36,"type":37},"2026-06-05","ACTUAL",{"date":39,"type":37},"2024-04-08",{"date":41,"type":22},"2026-08-31",{"name":43,"class":44},"Ann & Robert H Lurie Children's Hospital of Chicago","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100491258","hsi-for-intersegmental-plane-identification-during-sublobar-pulmonary-resections-100491258","NCT05676788","HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections","Hyperspectral Imaging for Intersegmental Plane Identification During Sublobar Pulmonary Resections in Lung Cancer Patients","HYPER-Seg","Inclusion Criteria:\n\n1. Histologically confirmed lung cancer stage I\u002FII or malignancy suspicious nodules\n2. Segmentectomy is oncologically indicated or impaired pulmonary and\u002For cardiac function prevent anatomical resection\n3. Male or female patients aged ≥ 18 years without upper age limit\n4. Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance (CrCl ≥ 50 mL\u002Fmin, Cockcroft-Gault formula)\n5. Total bilirubin ≤ 1.5 x upper limit of normal (except patients with Gilbert Syndrome (Morbus Meulengracht) in whom total bilirubin \\\u003C 3.0 mg\u002FdL is allowed)\n6. Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase)\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase) ≤ 2.5 x upper limit of normal\n7. Full legal capacity\n8. Written informed consent obtained according to international guidelines and local laws\n9. Ability to understand the nature of the trial and the trial related procedures and to comply with them\n\nExclusion Criteria:\n\n1. Requirement of a lobectomy or pneumonectomy to achieve complete resection\n2. Allergy to indocyanine green or iodine\n3. Hyperthyroidism\n4. Current or planned pregnancy, nursing period (if defined as requirement of clinical routine treatment)\n5. Medical condition which poses a high risk to undergo surgery as defined by the investigator\n6. Covid19 \u002F SARS-CoV2-infection at time of screening\n7. Participation in any other interventional clinical trial within the last 30 days before the start of this trial\n8. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed\n9. Known or persistent abuse of medication, drugs or alcohol\n10. Person who is in a relationship of dependence\u002Femployment with the coordinating investigator or the investigator","18 Years",{"count":56,"type":22},50,[58],"NA","The purpose of this study is the identification of the intersegmental plane and navigation during sublobar pulmonary resections in lung cancer using Hyperspectral Imaging, the comparison with ICG fluorescence intersegmental plane identification, and the establishment of automatic intersegmental plane navigation using machine learning strategies for intraoperative navigation.",[61,29],"Lung Neoplasm",[63,64,65,66,67,68],"Hyperspectral Imaging","Lung cancer","Segmentectomy","Indocyanine green","Intersegmental plane","Machine learning strategies","NOT_YET_RECRUITING","2023-01-06",{"date":72,"type":37},"2023-01-09",{"date":74,"type":22},"2023-04",{"date":76,"type":22},"2027-06",{"name":78,"class":44},"LungenClinic Grosshansdorf",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":45},"100466872","phase-2-a-combination-therapy-including-anti-pd-1-immunotherapy-in-mss-rectal-cancer-with-resectable-distal-metastasis-100466872","NCT05359393","A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis","Radiotherapy Followed by Chemotherapy and Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Liver\u002F Pulmonary Metastasis(Miracle-1): A Prospective, Single Arm, Multi-Center, Phase II Clinical Trial","Miracle-1","Inclusion Criteria:\n\n* Age 18\\~75;\n* Patient signs informed consent;\n* ECOG score 0\\~1;\n* Initial colonoscopy and pathology: adenocarcinoma;\n* MRI: rectal cancer located less than 10cm from the anus;\n* Imaging confirms that there are measurable metastases in the liver or lung, which are evaluated as NED acceptable by MDT discussion;\n* no previous treatment;\n* Patients have adequate organ function;\n* No contraindications to surgery or chemoradiation;\n* The relevant test results within 7 days before the first dose must meet the following requirements:\n\n  1. Blood routine examination (no blood transfusion within 7 days before screening, no correction with hematopoietic stimulating factor drugs):\n\n     * Hb≥90g\u002FL\n     * ANC≥1.5×10\\^9\u002FL; LC≥0.5×10\\^9\u002FL;\n     * PLT≥100×10\\^9\u002FL;\n     * WBC≥3.0×10\\^9\u002FL, ≤15×10\\^9\u002FL;\n  2. Blood chemistry (no blood transfusion or albumin within 7 days prior to screening):\n\n     * ALT, AST≤1.5 ULN;\n     * ALP≤2.5 ULN;\n     * TBIL≤1.5 ULN;\n     * Cr≤1.5 ULN, CrCL≥50 mL\u002Fmin;\n     * PT, APTT≤1.5 ULN, INR≤1.5 ULN(not receiving anticoagulation);\n  3. TSH is within the normal range; if TSH is out of the normal range, FT3 and FT4 should be investigated. If the test results of FT3\u002FFT4 cannot be obtained, T3 and T4 can be accepted. If the level of T3\u002FT4 is normal, the patients can be selected.\n  4. Urine test: urine protein\\\u003C2+; if the urine protein≥2+, the 24-hour urine protein quantification must be≤1g;\n  5. Echocardiography: LVEF≥55%;\n  6. 12-lead ECG: Fridericia corrected QTcF\\\u003C470 msec.\n* Expected survival time \\>6 months;\n* The gene status of KRAS, NRAS, BRAF and HER2 is clear;\n* Patients with microsatellite stability or mismatch repair protein defects;\n* Patients are willing and able to follow the protocol during the study, including receiving treatment and scheduled follow-up and examination.\n\nExclusion Criteria:\n\nPatients will not be accepted into this study if they meet any of the following criteria:\n\n1\\. History of tumor-related disease and treatment:\n\n1. Age \\\u003C18 or \\>75 years;\n2. other malignancy within 5 years, except adequately treated carcinoma in situ of the cervix or squamous cell carcinoma of the skin, or largely controlled basal cell carcinoma of the skin;\n3. malignant pleural effusion or malignant ascites;\n4. patients with severe medical comorbidities that preclude radiotherapy and surgery;\n5. previously treated;\n6. clinical or radiological evidence of spinal cord compression or a tumor within 3mm of the spinal cord on MRI\n7. the presence of distant metastases besides the liver and lungs, including brain, bone, ovarian, peritoneal and retroperitoneal multiple lymph node metastases;\n8. Patients who are considered suitable for using intense systemic treatment to achieve conversion after MDT discussion;\n9. pathological diagnosis of indolent cell carcinoma;\n10. patients with microsatellite instability or dMMR;\n11. patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. that require emergency surgical resection;\n\n2\\. Co-morbidities and treatment history:\n\n1. Presence of immunodeficiency disorders, including primary immunodeficiency disorders (e.g. caused by genetic factors) or secondary immunodeficiency disorders (e.g. caused by HIV infection or treatment related to immunological agents, etc.);\n2. Presence of any autoimmune disease that still requires treatment or a previous history of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, rheumatic heart valve disease, glomerulonephritis, etc. Excluding hypothyroidism due to autoimmune thyroiditis requiring only hormone replacement therapy and type I diabetes with manageable and stable blood glucose;\n3. known or suspected interstitial pneumonia; other moderate to severe lung disease that may interfere with the detection or management of drug-related pulmonary toxicity and severely affect respiratory function, including idiopathic pulmonary tissue fibrosis, mechanized pneumonia\u002Focclusive fine bronchitis, etc.;\n4. severe cardiovascular disease, including but not limited to conditions meeting NYHA criteria (Class III or higher), or myocardial infarction or cerebrovascular accident (cerebral ischaemia, symptomatic cerebral infarction, etc.) occurring within 3 months prior to the first dose, or unstable arrhythmia or unstable angina pectoris with coronary artery disease occurring within 1 month prior to the first dose, or congestive heart failure, or pre-existing symptomatic superior vena cava syndrome, etc.;\n5. an arteriovenous thrombotic event, such as deep vein thrombosis and pulmonary embolism, within the previous 3 months;\n6. history of live attenuated vaccination within 28 days prior to the first study dose or anticipated need for live attenuated vaccination during the study;\n7. active hepatitis B (defined as positive hepatitis B virus surface antigen \\[HBsAg\\] test result and HBV-DNA test value ≥ 500 IU\u002Fml);\n8. Hepatitis C (defined as a positive test result for hepatitis C virus antibody \\[HCV-Ab\\]) ;\n9. history of tuberculosis infection or treatment within 1 year prior to signing informed consent;\n10. presence of severe infection within 4 weeks prior to first dose, including but not limited to bacteremia requiring hospitalization, severe pneumonia, etc.; or active infection requiring systemic antibiotic therapy according to NCI-CTCAE v5.0 grade ≥ 2 within 2 weeks prior to first dose, or unexplained fever \\>38.5°C during screening\u002Fprior to first dose (at the investigator's discretion, due to oncologic causes fever due to tumor causes may be enrolled);\n11. previous allogeneic bone marrow transplantation or solid organ transplantation received or intended to be received;\n12. Hemoptysis with a maximum daily hemoptysis of approximately ≥2.5 ml within 2 months prior to signing informed consent; clinically significant bleeding symptoms or a clear bleeding tendency within 1 month prior to signing informed consent, e.g. gastrointestinal bleeding, bleeding gastric ulcer, fecal occult blood ++ at baseline, vasculitis; known hereditary or acquired bleeding and thrombotic tendencies, e.g. hemophilia, impaired coagulation skills, thrombocytopenia, hypersplenism, etc.;\n13. abnormal coagulation (INR \\> 1.5 or APTT \\> 1.5 × ULN) with bleeding tendency or undergoing thrombolysis or requiring long-term anticoagulation with warfarin or heparin, or requiring long-term antiplatelet therapy (aspirin ≥ 300 mg\u002Fday or clopidogrel ≥ 75 mg\u002Fday)\n14. peripheral neuropathy ≥ grade 2 according to NCI-CTCAE v5.0;\n15. Co-morbidities of other infectious diseases that are not suitable for participation in this study.","75 Years",{"count":89,"type":22},52,[91],"PHASE2","Although patients with locally advanced rectal cancer and resectable liver\u002Fpulmonary metastasis could benefit from surgery resection, these patients still have a poorer prognosis compared to those without distal metastasis. Based on previous studies, there is no confirmation of whether these patients could benefit from preoperative immunotherapy combined with conventional chemoradiotherapy. This study proposes a combination therapy, preoperative short-course radiotherapy followed by neoadjuvant chemotherapy and anti-PD-1 immunotherapy, for microsatellite-stable patients with locally advanced rectal cancer and resectable liver\u002Fpulmonary metastasis, to assess its impact on tumor retreat, decline of postoperative metastasis and recurrence, and the disease-free survival and overall survival of patients. Besides, this study will provide high-level medical evidence for future clinical treatment of patients with advanced rectal cancer.",[94,95,29,96],"Advanced Rectal Cancer","Liver Metastasis","Microsatellite Stable Colorectal Carcinoma","2022-11-09",{"date":99,"type":37},"2022-11-14",{"date":101,"type":22},"2022-12-01",{"date":103,"type":22},"2027-09-01",{"name":105,"class":44},"Fudan University"]